The QualityStocks Daily Monday, November 29th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(KRYS) $88.2400 +121.65%

Daily Trade Alert(ADGI) $46.8300 +86.43%

QualityStocks(ATXI) $1.7000 +53.15%

The QualityStocks Daily Stock List

Creative Medical Technology Holdings (CELZ)

We reported earlier on Creative Medical Technology Holdings (CELZD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (OTC: CELZ) is a clinical-stage biotechnology firm that is engaged in the treatment of various neurological, orthopedic, urological and immunological ailments such as stroke and erectile dysfunction, using adult stem cell treatments.

The firm is based in Phoenix, Arizona and was incorporated in 1998, on December 3. The enterprise, together with Creative Medical Health Inc. its affiliate company, is focused on regenerative medical solutions for unmet neurological and urological needs. Their team is made up of international researchers focused on regenerative medicine, whose approach to treatments makes sure that all treatments are proven to be both effective and safe.

Through partnerships with leading academic institutions and researchers, the firm has developed treatments for erectile dysfunction, established an extensive intellectual property portfolio, developed proprietary protocols and obtained Amniostem; a groundbreaking stem cell. The company is currently breaking new ground for the treatment of stroke using its amniotic-fluid based stem cell and recently launched a patient trial for erectile dysfunction at UCLA.

The firm’s product portfolio includes a treatment indicated for female infertility called OvaStem; a candidate developed for stroke patients, dubbed ImmCelz; Amniostem for the treatment of glioma, toxicity and strokes; a treatment developed for chronic lower back pain christened StemSpine; a candidate indicated for the treatment of genital dryness and loss of genital sensitivity and a treatment developed for erectile dysfunction called CaverStem.

Creative Medical Technology Holdings Inc. recently announced that the FDA issued an Investigational New Drug number to the firm’s ImmCelz candidate, which was developed to treat stroke patients. This is a major milestone for the firm and may lead to the candidate being approved for commercialization and use in the near future, which will be beneficial not only to the patients whose needs will be met but also to the company.

Creative Medical Technology Holdings (CELZD), closed Tuesday's trading session at $4.75, up 51.7572%, on 162,833 volume with 530 trades. The average volume for the last 3 months is 162,833 and the stock's 52-week low/high is $0.0014/$9.00.

GenTech Holdings, Inc. (GTEH)

QualityStocks, StockRockandRoll, PennyStockLocks, Penny Stock 101, Small Cap Firm, PennyStockScholar, OTCtipReporter, Insider Financial, PennyStockProphet, Profitable Trader Authority, Penny Pick Finders, Damn Good Penny Picks, HotOTC, StockHideout, StockOnion, Buzz Stocks, Penny Picks, Penny Stock Titans, MicroCapDaily, Fierce Analyst, Penny Stock General, TopPennyStockMovers, Planet Penny Stocks, Shiznit Stocks, StockWireNews, Penny Stock 102, OTCMagic, BeatPennyStocks and Penny Stock 108 reported earlier on GenTech Holdings, Inc. (GTEH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GenTech Holdings, Inc. is an emerging leader in the high-end CBD (cannabidiol) food and drinks marketplace. The Company is creating a national chain of Hemp Centric Coffee Shop Retail Spaces. This is where customers can relax, drink CBD infused teas and coffees, try different own-brand products, and experience holistic education and classes. GenTech Holdings is based in New York City. The Company’s shares trade on the OTC Markets.

GenTech will be offering alternatives to standard coffees, teas, and chocolate. In addition, it is building a broad outreach program working with medical practitioners throughout the nation in their own locations to educate their patients and increase awareness of the benefits of THC (Tetrahydrocannabinol) free CBD Products. All of this is offered under the brand 'The Healthy Leaf'.

In early 2020, the Company launched a high-end Coffee Subscription service called Secret Javas. Furthermore, GenTech earlier closed on its acquisition of SINFIT Nutrition, which offers a range of high-end Functional Foods. GenTech recently closed its acquisition on Products-Groups' "Hakuna Supply".

Recently, GenTech Holdings, through its SINFIT Nutrition brand, announced that it secured a new worldwide distribution partner, Saveco™. It recently shipped products to Saveco in Kuwait. It is now awaiting for the State of Kuwait's government to finalize the registration of the SINFIT brand for import and sale via Saveco's massive online presence and their different physical stores throughout the region.

Founded in 2013, Saveco is the latest subsidiary of Al-Qatami Group, founded by Mrs. Noor Al Qatami. Saveco is an all-inclusive one of-a-kind one-stop mega market in Kuwait. It has locations and sales outlets across the region. Their retail stores offer a considerable range of products and services. The assortment of services that Saveco offers include the Food Academy, Restaurants, Cafes, Juicing Shops, Perfume Stores, Florists, the Kid's Entertainment Area, and much more.

GenTech Holdings, Inc. (GTEH), closed Tuesday's trading session at $0.0007, up 27.2727%, on 99,118,474 volume with 244 trades. The average volume for the last 3 months is 99.118M and the stock's 52-week low/high is $0.0002/$0.0189.

Avenue Therapeutics (ATXI)

StocksEarning, MarketBeat, Zacks, StreetInsider, StockMarketWatch, TradersPro, Schaeffer's, Marketbeat.com, TradersPro Morning, SmallCapVoice, QualityStocks, PoliticsAndMyPortfolio and MarketClub Analysis reported earlier on Avenue Therapeutics (ATXI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avenue Therapeutics Inc. (NASDAQ: ATXI) (FRA: 49Y) is a specialty pharmaceutical firm that is engaged in the acquisition, licensing, development and commercialization of products that are mainly used in the intensive/acute care hospital setting.

The firm has its headquarters in New York and was incorporated in 2015, on February 9th. It operates in the healthcare sector, under the biotech and pharma sub-industry. The company is a majority-controlled subsidiary firm of Fortress Biotech Inc., which is a biopharmaceutical firm that is also engaged in the acquisition, development and commercialization of new biotechnology and pharmaceutical products.

The company develops intravenous Tramadol, which is currently undergoing phase 3 clinical trials for the treatment of moderate to severe post-surgical pain. The synthetic dual-acting opioid works by inhibiting noradrenaline and serotonin re-uptake and blocking spinal level nociceptive impulses and could be used as an alternative for conventional opioids. The oral formulation of this candidate is marketed in the U.S. for moderate to severe pain in grown-ups. Its parenteral formulations include subcutaneous and intramuscular formulations. The drug itself is marketed in the U.S. under the Ultram trade name. Ultracet, which is a combination product of acetaminophen and tramadol, is also sold in the U.S.

The firm is pursuing regulatory approval for its IV tramadol drug formulation, after the FDA cited in their Complete Response Letter that they did not find any controls, manufacturing or chemistry issues with its candidate. If successful, the firm will introduce the drug to the market, which will increase its revenue and boost share prices as well encourage more investments into the firm.

Avenue Therapeutics (ATXI), closed Tuesday's trading session at $1.7, up 53.1532%, on 15,137,424 volume with 28,190 trades. The average volume for the last 3 months is 15.137M and the stock's 52-week low/high is $1.02/$7.69.

Pioneer Power Solutions, Inc. (PPSI)

MarketClub Analysis, TradersPro, QualityStocks, Wall Street Resources, StockMarketWatch, TraderPower, Marketbeat.com, Trading Concepts, Trades Of The Day, The Street, Street Insider, MarketBeat and Investing Futures reported earlier on Pioneer Power Solutions, Inc. (PPSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pioneer Power Solutions, Inc. engages in the manufacture, sale, and service of electrical transmission, distribution, and on-site power generation equipment. This is for applications in the utility, industrial, commercial, as well as backup power markets. Its main products include switchgear and engine-generator controls, complemented by a national field-service network to maintain and repair power generation assets.

Established in 2008, Pioneer Power Solutions has its head office in Fort Lee, New Jersey. The Company lists on the NasdaqCM (Nasdaq Capital Market). Pioneer Power Solutions, Inc. is a subsidiary of Provident Pioneer Partners, L.P.

Pioneer Power Solutions’ business operations cover about 200 employees at seven manufacturing, engineering, sales, and marketing locations in the United States. The Company is an industry leader in the design and manufacture of electrical equipment for customers in the North American industrial, commercial, OEM (Original Equipment Manufacturer) and critical power markets. Its product portfolio includes a broad spectrum of specialty magnetic products used in the control and conditioning of electrical current for critical processes.

Pioneer’s T&D Solutions business provides equipment solutions that help customers effectively and efficiently manage their electrical power distribution systems to desired specifications. Pioneer’s Critical Power business provides engine-generator sets and controls. The Critical Power business is supported by the Company’s nationwide field service organization for emergency standby power systems and distributed generation applications.

Pioneer Power Solutions previously announced that it secured a $3.5 million order from a large global container shipping company. Pioneer will supply a highly customized energy solution, including two integrated power centers with redundant 15kv medium voltage switchgear, an integrated power control building, and an integrated double-ended 750kva unit substation. The equipment will help deliver reliable and redundant power to the shipping company's main terminal in Hawaii.

Pioneer Power Solutions also announced that it was awarded an initial service contract for preventative maintenance and repairs by one of the largest home improvement retailers in the United States. Pioneer will provide scheduled generator preventative maintenance and emergency repair services for the retailer’s engine generator equipment assets at 24 of its greater than 300 store locations.

Pioneer Power Solutions, Inc. (PPSI), closed Tuesday's trading session at $7.63, up 27.1667%, on 21,422,443 volume with 90,540 trades. The average volume for the last 3 months is 21.422M and the stock's 52-week low/high is $3.0904/$12.44.

Provention Bio Inc. (PRVB)

MarketBeat, StockMarketWatch, MarketClub Analysis, Kiplinger Today, InvestorPlace, TradersPro, QualityStocks, PoliticsAndMyPortfolio, Wealth Insider Alert, Trades Of The Day, TopPennyStockMovers, StreetInsider, Schaeffer's and InvestorsUnderground reported earlier on Provention Bio Inc. (PRVB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Provention Bio Inc. (NASDAQ: PRVB) (FRA: 2VB) is a clinical stage biopharmaceutical firm that is focused on developing and commercializing therapeutics and solutions that prevent immune-mediated illnesses.

The firm has its headquarters in Red Bank, New Jersey and was incorporated in 2016, on October 4th by Ashleigh Palmer and Francisco Leon. It serves consumers in the United States, with a focus on New Jersey.

The company is party to a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd, which entails the development and commercialization of a bispecific antibody-based molecule dubbed PRV-3279 that targets the B cell surface proteins CD79B and CD32B in China. It is also party to a license and collaboration agreement with Amgen Inc., which involves the development of an anti-IL-15 monoclonal antibody known as PRV-015, which is indicated for the treatment of gluten-free diet non-responsive celiac disease.

The enterprise’s product pipeline comprises of a coxsackie virus B vaccine known as PRV-101, which is indicated for the prevention of the onset of type 1 diabetes and acute CVB infections; a formulation dubbed PRV-3279, which has concluded phase 1b clinical trials evaluating its effectiveness in treating lupus; and an oral CSF-1R inhibitor dubbed PRV-6527, which has concluded a phase 2a clinical trial testing its efficacy in treating Crohn’s disease. It also develops PRV-031 which is in phase 3 clinical trials for type 1 diabetes.

The company’s PRV-031 formulation may soon receive approval from the FDA based on the latest results from its clinical trial, which brings them one step closer to providing the drug to patients with type 1 diabetes who are at risk of developing end-stage insulin-dependent disease. The formulation’s approval will help address an unmet need while also bringing in additional revenue into the company.

Provention Bio Inc. (PRVB), closed Tuesday's trading session at $6.56, off by 6.5527%, on 606,577 volume with 6,947 trades. The average volume for the last 3 months is 606,577 and the stock's 52-week low/high is $5.59/$20.05.

Granada Gold Mine (GBBFF)

BabyBulls, QualityStocks and Investor Ideas reported earlier on Granada Gold Mine (GBBFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Granada Gold Mine Inc. (OTC: GBBFF) (FRA: B6DA) is a junior natural resource firm that is focused on exploring for, acquiring and developing mineral properties.

The firm has its headquarters in Coquitlam, Canada and was incorporated in 1985, on July 17th. Prior to its name change in January 2017, the firm was known as Gold Bullion Development Corp. It serves consumers in Canada.

The company is involved in the mining and industrial metals business sector. It has silver and gold properties in Ontario and Quebec. The company’s operations are carried out either through consulting agreements with 3rd parties or directly. It is currently focused on the continued exploration of its Granada Property.

The enterprise’s Granada property is found along the Cadillac Trend in an established mining district about 5 kilometers south of Rouyn-Noranda. The Cadillac break shear zone is hosted in younger syenite sills, granites and Pontiac metasedimentary ricks. This property is made up of two mining leases, i.e. BM 852 and BM 813, one CLD claim, 25 CL claims and 24 CDC claims, which cover a total of about 1,474 hectares. The Granada deposit is a mesothermal quartz-vein gold deposit hosted by younger syenite porphyry dykes.

The firm recently commissioned test work on mineralized material at its Granada property after the discovery of a rare alkali metal known as rubidium. The metal has been used as an electrolyte to enhance the efficiency cycle of sodium-ion batteries. While the size of the deposit is yet to be determined, it could afford the firm entry into the rapidly growing sodium-ion storage battery market, which may be good for its growth and investments.

Granada Gold Mine (GBBFF), closed Tuesday's trading session at $0.0698, off by 8.1579%, on 52,990 volume with 7 trades. The average volume for the last 3 months is 52,990 and the stock's 52-week low/high is $0.066/$0.1892.

InCapta Inc. (INCT)

QualityStocks, PennyStockOracle, PennyStocks24, DSR News, FeedBlitz, HoleinOneStocks.net, LuckyStockPicks, PennyStockRewards.com, PennyStockShark, ProMarketLive, Promotion Stock Secrets, Pumps and Dumps, StockProfessors, USA Market News, The Stock Psycho, Jet-Life Penny Stocks, Topgun stockpicks, OTPicks, Liquid Pennies, PowerPennyStocks, PowerPennyStocks.com, HEROSTOCKS, Fast Money Alerts, PennyStock Tweets, Otcstockexchange, Wallstreetbuzz, Value Penny Stocks, MassiveStockProfits, Joe Penny Stocks, OTCPicks, Liquid Tycoon, Hot Stock Profits, Penny Stock Newsletter, FOX Penny Stocks, WePickPennyStocks, Elite Stock Alerts, Whisper from Wall Street, Damn Good Penny Picks, BestStocksDaily, HotStockProfits, TheMicrocapNews, Stock Shock and Awe, Stock Guru, SeriousTraders, RockingPennyStocks, RisingPennyStocks, Super Hot Penny Stocks, Super Nova Stock Picks, PREPUMP STOCKS, Penny Stock Hub, Pennystocktweeters.com, Penny Picks, Winning Penny Stock Picks, Ascending Stocks, PennyPickAlerts, Penny Stock Pick Report, Penny Stock Pick Alert, StockMister, Penny Stock MoneyTrain, Penny Stock General and PHUB News reported earlier on InCapta Inc. (INCT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

InCapta Inc. (OTC: INCT) is a media holding investment firm that is engaged in the provision of development services for online radio, television and entertainment industries.

The firm has its headquarters in Cheyenne, Wyoming and was incorporated in June 1997. It operates as part of the radio and television broadcasting industry. The firm has three companies in its corporate family and serves consumers in the United States.

The company works with clients to operate, market and develop online cloud television networks and other entertainment projects. It is fully committed to meeting and exceeding its expectations by participating in different fields of online business models. The company is currently seeking out and evaluating investment opportunities which have the potential to earn reasonable returns.

The enterprise operates through its subsidiaries, i.e. Leading Edge Radio Network and Banana Box Wholesale Grocery. It offers management consulting services to various sectors in the economy and also arranges for clients’ online presence via social media. It is also involved in the pre-production of two full-length movies, in addition to producing radio talk shows on Leading Edge Radio Network and developing half-hour television shows. The enterprise is also developing an online movie channel and owns a nationwide wholesale grocery operation with clients in more than 45 states.

The company is focused on starting new ventures and making investments in portfolio firms that it believes are attractive. This may have a positive influence on investments into the company as well as its overall growth.

InCapta Inc. (INCT), closed Tuesday's trading session at $0.0003, even for the day, on 37,764,696 volume with 64 trades. The average volume for the last 3 months is 37.765M and the stock's 52-week low/high is $0.000001/$0.0057.

Safeplus International (ACAI)

We reported earlier on Safeplus International (ACAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Safeplus International Holdings Limited (OTC: ACAI) is focused on the development and marketing of different technologies for the medical device industries.

The firm has its headquarters in Pittsford, New York and was incorporated in 1968, on August 11th by Michael L. Weiner and Wilson Greatbatch. Prior to its name change in September 2020, the firm was known as Biophan Technologies Inc. It serves consumers in the United States.

The company has several areas of technology development and research but is primarily involved in the business of surgical and medical instruments and apparatus. It seeks partners to monetize its patented technologies, which include its biothermal pulsewidth modulation and power supply technology, to improve the performance of neuro-stimulators and pacemakers, and nanomaterials and photonics patents.

The enterprise’s current focus is the circulatory system, which is why it owns a minority equity position in a firm devoted to repairing hearts, known as Myotech. Its products and technologies include MRI (Magnetic Resonance Imaging) Safety and MRI compatibility. The MRI Image compatibility include catheters, guidewires, vena cava filters and stents. Catheters and guidewires are used in resonators and coatings to improve imaging. Vena cava filters are used for MRI visualization of blood clots while stents are used for MRI evaluation of in-stent restenosis.

The company is focused on entering into opportunities which will generate more revenue while also growing its position in the medical device industry market. This move may have a positive effect on the company’s growth as well as encourage more investments into the company.

Safeplus International (ACAI), closed Tuesday's trading session at $0.15999, even for the day. The average volume for the last 3 months is 1,500 and the stock's 52-week low/high is $0.10/$3.00.

Acro Biomedical (ACBM)

We reported earlier on Acro Biomedical (ACBM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Acro Biomedical Co. Ltd (OTCQB: ACBM) is a biotech firm that is focused on the development and marketing of nutritional products which promote a healthy lifestyle.

The firm has its headquarters in Fishers, Indiana and was incorporated in 2014, on September 24th. Prior to its name change in January 2017, the firm was known as Killer Waves Hawaii Inc. It serves consumers around the globe.

The company is focused on entering into agreements with major science and technology biomedical research centers and research institutes in Taiwan to help realize its objectives. It is also party to a collaboration agreement with Animal Technology Laboratories of Agricultural Technology Research Institute, which entails the development of medical-grade regenerative biomaterials.

The enterprise provides embryonic, antrodiacinnamomea, marine elements, metallothionein and cordycepin nutrients. Marine elements are a group of trace multi-peptides which are also referred to as marine embryonic elements while metallothionein is a rare micro protein. It plans to carry out research on some of its products based off of cordycepssinensis. Cordyceps is a fungi used in making traditional Chinese medicine. Cordycepssinensis is a medicine in old Tibetan and Chinese medicine. The medicine is a unique combination of a fungi and caterpillar.

The firm is focused on venturing into new markets, having recently announced that it would be developing cordyceps-infused chicken feed. This move, if successful, may bring in additional revenue into the firm as well as extend its consumer reach, which will be good for its growth.

Acro Biomedical (ACBM), closed Tuesday's trading session at $4.18, even for the day. The average volume for the last 3 months is 224 and the stock's 52-week low/high is $1.01/$9.00.

Pfizer Inc. (PFE)

The Street, InvestorPlace, StockMarketWatch, Kiplinger Today, The Online Investor, Schaeffer's, MarketClub Analysis, StreetInsider, Market Intelligence Center Alert, Daily Trade Alert, StreetAuthority Daily, Zacks, Money Morning, TopStockAnalysts, Trades Of The Day, MarketBeat, Investors Alley, StocksEarning, INO.com Market Report, Louis Navellier, Investopedia, Barchart, SmarTrend Newsletters, The Wealth Report, Uncommon Wisdom, Top Pros' Top Picks, Daily Wealth, Wealth Insider Alert, ProfitableTrading, Street Insider, The Street Report, Profit Confidential, Market FN, CNBC Breaking News, The Best Newsletters, Daily Profit, The Motley Fool, Money and Markets, Wyatt Investment Research, Wealth Daily, Dividend Opportunities, AllPennyStocks, Cabot Wealth, Investment U, Daily Markets, Investor Guide, Stock Research Newsletter, MarketWatch, AnotherWinningTrade, Market Intelligence Center, Marketbeat.com, TradingMarkets, Investing Daily, Streetwise Reports, WStreet Market Commentary, Coattail Investor, Total Wealth, TheStockAdvisor, GorillaTrades, SmallCapVoice, Trading Markets, StrategicTechInvestor, Inside Investing Daily, StreetAlerts, CustomerService, Power Profit Trades, Wall Street Daily, SmallCap Network, Trade of the Week, InvestorGuide, Insider Wealth Alert, CRWEFinance, Darwin Investing Network, Market Authority, Investor Update, InvestorsObserver Team, DrStockPick, Forbes, PennyOmega, StockHotTips and PennyToBuck reported earlier on Pfizer Inc. (PFE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shares of Pfizer Inc. (NYSE:PFE) traded today at $55.70, eclipsing its 52-week high. Approximately 40.2 million shares have changed hands today, as compared to an average 30-day volume of 35.7 million shares.

Pfizer Inc. (NYSE:PFE) is currently priced 50.7% above its average consensus analyst price target of $26.50.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

In the past 52 weeks, Pfizer Inc. share prices are bracketed by a low of $33.36 and a high of $55.70 and is now at $53.73, 61% above that low price.

Pfizer Inc. (PFE), closed Tuesday's trading session at $52.4, off by 2.963%, on 72,660,758 volume with 453,890 trades. The average volume for the last 3 months is 71.835M and the stock's 52-week low/high is $33.36/$55.70.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, Schaeffer's, Kiplinger Today, QualityStocks, MarketBeat, StockMarketWatch, StreetInsider, TradersPro, The Street, StocksEarning, Trades Of The Day, Daily Trade Alert, TopPennyStockMovers, TraderPower, BUYINS.NET, Zacks, Wealth Insider Alert, Early Bird, Jason Bond, Cabot Wealth, InvestorsUnderground, PoliticsAndMyPortfolio, StockOodles, The Online Investor, Marketbeat.com, Profitable Trader Authority, Stock Beast, Wealth Daily, Energy and Capital, The Best Newsletters, Daily Market Beat and The Wealth Report reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric vehicle (“EV”) technology is constantly evolving. With the EV industry being only a decade old, the technology used to power EVs is still in its infancy. Researchers are constantly working to increase battery capacity and charging speed, make EVs more aerodynamic and optimize software. High-speed EV racing competitions have emerged as quite an effective means of showcasing electric vehicles and advancing EV technology. These events allow developers to put new tech to the test under extreme conditions to find out their limits and how they can be improved.

Formula E, for instance, is an international championship for battery electric vehicles (“BEVs”) that has been around for quite a while already. The championship kicked off in July 2016 in Beijing, China, and included events such as the E-Prix in 20 cities around the world. Over the past couple of years, more EV racing championships have cropped up including the Extreme E race series, SuperCharge, which will kick off in 2022 in cities around the world, and the eSkootr Championship, also launching next year. The latter is quite unique as it will feature electric scooters capable of going up to 62 mph (100 kmph).

These sleek electric scooters look nothing like the clunky scooters you see on the streets. The S1-X, which was designed by motorsport technology company YCOM, will be used in the event. It has a carbon fiber chassis, inflatable tires and a 1.5-kilowatt hour battery along the bottom of the chassis. Founder Nicola Scimeca says the e-scooter offers an “unexpectedly steady” ride and. like all EVs, runs quietly.

The company built the S1-X from the ground up, figuring out the design and how riders would handle it along the way. At high speeds, for example, riders have to swiftly adjust their stance on corners, and this can be physically draining.

The e-scooter’s small battery lasts only four to five minutes at high speeds, Scimeca says, with a single charge covering three to four heats before running out. Roger Griffins, team principal at Andretti United Extreme, says charging presented a significant challenge, especially since most of the team has a history in conventional motorsports featuring internal combustion cars. On average, it takes around an hour to cool down, fuel and inspect an ICE car compared to four hours to recharge a depleted EV battery.

Racing EVs also call for different safety considerations in case of crashes due to all the high-voltage electronics they feature. Once these considerations are sufficiently tested under extreme, high-speed conditions, they can be applied to ordinary electric vehicles. Furthermore, Extreme E and Formula E cars feature silicon carbide semiconductors that allow for more efficient power transfer, potentially adding dozens of extra miles to the range. Once it is perfected, this technology could eventually trickle down to regular electric cars.

Other technologies already manifesting in the EV space include the integration of drone technology in electric vehicles as implemented by entities such as Workhorse Group Inc. (NASDAQ: WKHS). This technology enables fleets to optimize their energy use and ensure delivery route efficiency.

Workhorse Group Inc. (WKHS), closed Tuesday's trading session at $5.89, up 1.7271%, on 5,053,585 volume with 30,770 trades. The average volume for the last 3 months is 5.018M and the stock's 52-week low/high is $5.64/$42.96.

Biofrontera Inc. (BFRI)

Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter and MarketBeat reported earlier on Biofrontera Inc. (BFRI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Biofrontera (NASDAQ: BFRI, BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, has closed its underwritten initial public offering of 3,600,000 units. According to the update, each unit consisted of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a per-unit public offering price of $5.00. The warrants have an exercise price of $5.00 per share and are exercisable for five years after the issuance date. In addition, the underwriters exercised in full their option to purchase up to an additional 540,000 warrants. Roth Capital Partners acted as Joint Book-Running Manager for the offering, which closed on Nov. 2, 2021.

To view the full press release, visit https://ibn.fm/izvQS

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy (“PDT”) and topical antibiotics. The company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information about the company, visit www.Biofrontera.com.

Biofrontera Inc. (BFRI), closed Tuesday's trading session at $7.1, off by 10.1266%, on 74,642,371 volume with 343,610 trades. The average volume for the last 3 months is 74.029M and the stock's 52-week low/high is $2.2501/$10.40.

The QualityStocks Company Corner

FingerMotion Inc. (OTCQX: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (OTCQX: FNGR) .

  • U.S.-based FingerMotion is a technology innovator focused on smart communication applications in China’s mobile-hungry billion-plus population
  • The company’s big data services are relatively new in development but already play a significant role in the insurtech industry’s global growth trends
  • While most of FingerMotion’s revenues are derived from its SMS and MMS products, executives anticipate its big data services will eventually be the company’s largest driver of profits
  • The insurtech industry has already generated record annual deal-making this year as of the third quarter, outpacing all of 2020 by 48 percent

The insurtech industry has turned 2021 into a record year for business, with deals that have already outpaced all of 2020, by approximately 48 percent, as of the end of the third quarter. Analysts at CBInsights reported insurtechs had raised $10.5 billion across 427 deals by the quarter’s end (https://ibn.fm/tyVjH). China communications technology solutions provider FingerMotion (OTCQX: FNGR) plays a part in the trend, inking a big data outlook deal with global insurer Pacific Life early in the year to provide data analytics for Pacific Life’s Re-insurance division, and adding two brands last month that will generate value-add underwriting services by covering mobile consumer device maintenance needs (https://ibn.fm/5CGwk).

FingerMotion Inc. (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Monday’s trading session at $5.85, up 0.171233%, on 7,765 volume with 55 trades. The average volume for the last 3 months is 7,765 and the stock's 52-week low/high is $3.22/$17.00.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that it will host the first Sequire Clean Tech & EV Conference, slated to take place from 8 a.m. through 5 p.m. ET on Dec. 6, 2021. The one-day investor event will feature prominent electric vehicles, energy and power, materials and chemicals, and food and agriculture companies. As businesses and consumers worldwide gravitate toward more sustainable practices, SRAX is excited to host a full day of networking and learning with the premier innovators in the clean tech space. “With the new infrastructure bill in place, we can hope to see adoption and growth within the clean technology and electric vehicle industry in the years to come,” said Morgan-Lea Fogg, community development director at SRAX. “We are looking forward to exploring this further within our panels and hearing from experts on trends as we host you for the last Sequire event of the year.” To view the full press release, visit https://ibn.fm/VIsUA

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Monday’s trading session at $5.25, up 3.1434%, on 211,478 volume with 1,012 trades. The average volume for the last 3 months is 211,478 and the stock's 52-week low/high is $2.37/$7.29.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

  • InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials
  • The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million
  • Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales
  • InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders
  • Preclinical data of INM-088, the company’s cannabinol (“CBN”) formulation for the treatment of glaucoma, show CBN’s effectiveness in reducing cell death in retinal ganglion cells

For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of its programs. And in a business update accompanying the release of its Q1 2022 financial results, the company discussed this momentum in relation to the progress made thus far (https://cnw.fm/dLKoa).

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Monday’s trading session at $1.99, up 18.4524%, on 4,511,295 volume with 10,740 trades. The average volume for the last 3 months is 4.444M and the stock's 52-week low/high is $1.2545/$6.42.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products manufactured by Bidi Vapor LLC, today announced the results of a newly published study. According to the update, the study found Bidi Vapor's premium electronic nicotine delivery system (“ENDS”), a disposable device branded BIDI(R) Stick, mimicked the blood levels of nicotine when subjects smoked their usual brand of combustible cigarette, potentially providing a satisfying alternative to cigarette smoking. In research published in November 2021, comparative blood samples revealed a dramatic alignment between combustible cigarettes and BIDI Sticks (both tobacco and flavored products). “This study shows that the BIDI Stick can be a meaningful, nicotine delivery alternative for adult smokers aged 21 and older,” said Niraj Patel, president and chief executive officer of Bidi Vapor and Kaival Brands. “We are submitting this data to the FDA as part of our Premarket Tobacco Product Application (‘PMTA’) and believe the scientific evidence supports that the BIDI Stick is appropriate for the protection of the public health.” To view the full press release, visit https://ibn.fm/mSeBM

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Its vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. In line with this vision, Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor LLC, which are intended exclusively for adults 21 and over.

Kaival Brands is on a mission to set the highest standard and elevate the adult consumer experience for vaping. The company is headquartered in Grant, Florida.

Bidi® Stick

Bidi® Stick, Bidi Vapor LLC’s primary offering, is the fastest-growing closed system disposable electronic nicotine delivery system (ENDS) in the U.S.

Intended exclusively for adults 21 and over, the one-time use device is designed with premium features, including a high-quality battery, satisfying Class A nicotine offering consistently smooth throat hits and an aluminum body. Bidi Stick is ready to use straight from the package, providing a consistent and precise amount of nicotine with every draw.

Bidi Stick and all Bidi Vapor products are sold primarily through national convenience stores, as well as online exclusively through authorized direct retailers and GoPuff, the digital convenience store.

Bidi® Cares Initiative

The tamper-resistant Bidi Stick is the only ENDS on the market with an ecologically friendly, mass-recycling program. The Bidi® Cares initiative focuses on promoting sustainable practices to save the environment, one step at a time, through proper disposal of vapor products.

Through Bidi Cares, Kaival Brands and Bidi Vapor aim to promote and educate consumers on the dangers of improper waste disposal.

Bidi® Pouch

On January 26, 2021, Kaival Brands took a step toward building on the success of Bidi Vapor’s e-cigarette device when it announced the debut of the Bidi® Pouch. Officially launching in early February, the Bidi Pouch provides a tobacco-free nicotine formulation packed in an easy-to-go tin can, available in six flavors.

“We are excited that Bidi Vapor continues to develop and innovate new ways to bring the Bidi Vapor experience to adult consumers. Bidi Vapor’s new Bidi Pouch offering, which we will exclusively distribute, is just another example of our ability to meet the demands of the marketplace,” Niraj Patel, CEO of Kaival Brands, stated in the news release. “The pouch marketplace is yet another opportunity to demonstrate Bidi Vapor’s premium experience to adult users. We believe that Bidi Vapor’s share of the nicotine pouch market will rival Bidi Vapor’s market share achievement in vape. It represents a significant opportunity for us as the exclusive distributor of Bidi Vapor’s products in 2021 and beyond.”

Recent Corporate Developments

  • March 1, 2021: Kaival Brands announced its entry into two new distribution agreements boosting the company’s potential store count for Bidi Vapor products to over 54,000 – a 500% increase over 2020. Patel noted in the news release that this milestone, along with recent corporate developments, has the company “feeling extremely confident about [its] fiscal year 2021 revenue guidance range of $400m – $450 million.”
  • March 16, 2021: The company reported $37.4 million in revenue for the fiscal quarter ended January 31, 2021. This figure brought its cumulative revenues since commencing business operations in March 2020 to roughly $100 million, despite revenue slowdowns during the fourth quarter of 2020 as a result of packaging and labeling updates. Patel forecast an increase to revenues during Kaival Brands’ second fiscal quarter ending April 31, 2021. He also reaffirmed the company’s confidence in its fiscal 2021 revenue guidance.
  • March 18, 2021: Kaival Brands announced its appointment of three new directors to its board ahead of its proposed uplisting to the Nasdaq Capital Market. The appointments of Paul Reuter, Carolyn Hanigan and Roger Brooks as independent directors are intended to ensure the company complies with certain Nasdaq corporate governance rules.
  • March 31, 2021: The company announced that Bidi Vapor LLC has successfully completed the regulatory process to enter four new, significant markets – the U.K., Australia, New Zealand and Russia.

Market Outlook

The U.S. e-cigarette and vape market was valued at $6.09 billion in 2020, according to data from Grand View Research. The firm expects the industry to expand at a compound annual growth rate of 27.3% from 2021 to 2028, with growth factors including rising awareness of tobacco alternatives.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Pune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Paul Reuter is a Director of Kaival Brands. He brings to the company nearly five decades of industry experience in small box retail as a journalist, editorial director, entrepreneur and speaker. Mr. Reuter has launched two successful businesses, including MidWest Retail Group LLC, which was the largest U.S. 7-Eleven franchise group, where he served as Chairman and founding partner from April 2013 through June 2019. He is also the founder of Kreative Collaborations LLC, an industry consultancy.

Carolyn Hanigan is a Director of Kaival Brands. She served as the President of Reynolds American Innovation Company, an operating company of Reynolds American Inc. (“RAI”), from January 2016 to June 2018. Ms. Hanigan also led the global vapor collaboration with British American Tobacco (“BAT”) up until RAI was acquired by BAT in 2017. She served as the architect of RAI’s U.S. reduced risk products strategic direction to further the vision of transforming tobacco, preparing the U.S. commercial execution and regulatory applications for a wide array of products, including the Glo tobacco heating products; the Velo nicotine pouches; and the Alto, Ciro, Vibe and Solo nicotine vaporizers. Ms. Hanigan holds a Bachelor’s degree in business from Boston College and a Master of Business Administration degree from St. Mary’s College.

Roger Brooks is a Director of Kaival Brands. Since 2005, he has served as the Chairman, Treasurer and Co-Founder of Abierto Networks. Prior to his roles with Abierto, Mr. Brooks was the lead independent director and a member of the compensation and audit committees for Moldflow Corporation, a Nasdaq-listed software firm that was sold to Autodesk Inc. in 2008. He holds a Bachelor of Arts degree from the University of Connecticut and a Master of Business Administration degree from New York University, Stern Graduate Business School. He is also a graduate of the Stanford University Executive Management Program.

Kaival Brands Innovations Group Inc. (KAVL), closed Monday’s trading session at $1.3, up 6.5574%, on 774,583 volume with 1,693 trades. The average volume for the last 3 months is 754,536 and the stock's 52-week low/high is $1.21/$43.80.

Recent News

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), an emerging leader in innovative health and wellness beverages and products, announced that at its annual general and special meeting of shareholders (“AGM”) all agenda items were approved. The meeting was held on Nov. 24, 2021. Included in the agenda items were the election of directors and the appointment of an auditor. According to the company, four individuals were elected to the board, including Marcello Leone, John Campbell, Martino Ciambrelli and Phil Fontaine. In addition, Dale Matheson Carr-Hilton Labonte LLP (“DMCL”) was reappointed as the company auditor for the next year. To view the full press release, visit https://ibn.fm/CDY7i

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

  • Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
  • Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
  • Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
  • Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
  • Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH).

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Monday’s trading session at $0.2002, up 0.744767%, on 68,941 volume with 38 trades. The average volume for the last 3 months is 68,941 and the stock's 52-week low/high is $0.172/$1.20.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, is spotlighted in a recent Power Play interview released by the Market Herald. FuelPositive CEO Ian Clifford talked with Power Play’s Dave Jackson during the interview, down with CEO Ian Clifford to discuss NHHHF’s recent announcement of its operational costing model and timeline for a green ammonia production system. Clifford noted that the company's initial systems are estimated to produce up to 100 tons of green anhydrous ammonia per year at a cost of C$560 per metric ton. The company plans to implement its proprietary pilot systems in 2022 with serial manufacturing expected to begin sometime in 2023. FuelPositive provides clean-energy solutions, including carbon-free ammonia, for use across a broad spectrum of industries and applications. The Power Play by The Market Herald provides investors with a quick look of what they need to know about a company's latest press release through exclusive insights and interviews with company executives. To view the full interview, visit https://ibn.fm/xCLN0. To view the full press release, visit https://ibn.fm/VGO2s   

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Monday’s trading session at $0.1605, up 3.0829%, on 1,495,647 volume with 282 trades. The average volume for the last 3 months is 1.496M and the stock's 52-week low/high is $0.03224/$0.326.

Recent News

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, has finalized its previously announced acquisition of Hearing Assist II LLC. An established leader in the direct-to-consumer hearing aid market, Hearing Assist reports more than 500,000 hearing aids sold and top-line revenues of more than $72 million since 2018; the company is Walmart's largest hearing aid supplier. According to the agreement, the acquisition transaction included a total of $10 million equivalent of InnerScope's restricted shares of common stock subject to a 24-month leak-out agreement. Under the agreement, HearingAssist will continue to operate under Hearing Assist Direct Inc., a wholly owned InnerScope subsidiary; InnerScope retained the same management and operations team. “Today is a tremendous milestone for InnerScope,” said InnerScope president and CEO Matthew Moore in the press release. “I'm delighted to welcome the HearingAssist team, who share our passion for providing convenient and affordable hearing products for the tens of millions of Americans who suffer from hearing loss. The HearingAssist acquisition is another meaningful step in advancing our strategy to grow as a leader and innovator in the direct-to-consumer hearing aid market. Moreover, adding HearingAssist and its management team with their proven track record should continue generating millions of dollars in sales revenues with Walmart in-store displays and Walmart.com and through its online website. . . . I'm excited about InnerScope's next chapter, as we continue to drive growth with increased revenues to create long-term value for shareholders." To view the full press release, visit https://ibn.fm/6QUw2

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

  • First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
  • Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
  • The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
  • Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store, MyHearIQ.com, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (https://ibn.fm/bRWUb).

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Monday’s trading session at $0.0166, up 29.6875%, on 200,602,623 volume with 3,275 trades. The average volume for the last 3 months is 200.603M and the stock's 52-week low/high is $0.000001/$0.098.

Recent News

DealMaker

The QualityStocks Daily Newsletter would like to spotlight DealMaker.

DealMaker is the leading technology solution for companies looking to raise capital faster and more efficiently. Companies of all sizes – from startups to blue chips – use DealMaker to launch and market their offerings to investors across the globe.

DealMaker is the only complete solution for companies raising capital, providing a seamless investor experience and a complete deal CRM with real-time data and analytics, as well as investor management and engagement tools. Companies using DealMaker complete their raises up to 75% faster and over 80% cheaper than traditional methods of capital raising.

Since its founding in 2017, nearly 1,000 capital raises have been completed on DealMaker, including some of the most successful raises in the past three years.

DealMaker has offices in Toronto, Ontario, and Tampa, Florida.

Solutions for Any Type of Capital Raise

A Seamless Investor Journey

Whether investors start their journey by clicking an ‘Invest Now’ link or by receiving a custom email invitation, DealMaker leverages a proprietary question flow that allows investors to complete their subscription agreement in minutes as opposed to hours.

DealMaker digitizes and breaks down the subscription agreement into its core components to ensure investors are only answering the questions relevant to them. This helps to guarantee that investments are secured at the time of interest and with no deficiencies. Companies raising on DealMaker have significantly lower costs, as much as 90% less, due to the elimination of document review and back-and-forth.

Digital Payments, AML and Accredited Investor Verification

The investors’ journey doesn’t end when they sign the subscription agreement. DealMaker has the most robust suite of payment options, including credit card and secure bank-to-bank transfers, to allow investors to pay for their investments immediately and using the methods they prefer. Digital payments increase conversion rates and average investment amounts on every type of deal by removing friction in the payment process.

DealMaker also has automated AML built into the platform – a feature that’s crucial for any marketed raise, including Reg A+ and Crowdfunding, but also anytime investments are accepted from unknown investors. For 506c raises, DealMaker also has Accredited Investor Verification built into the platform, eliminating painful back-and-forth to ensure investors are verified.

In addition to ensuring that the investor has a seamless journey, Digital payments, AML and Accredited Investor Verification efficiently remove the pain of managing payments, background checks and verification from the company raising capital.

A Complete CRM for the Raise

Raising capital can be an arduous process, particularly when it comes to managing back-and-forth and investor follow-up to get the deal closed. DealMaker eliminates that pain by providing a full deal CRM to all companies raising on its platform.

DealMaker offers real-time data on investor progress and payments, automated reminders to drive conversion, contact information and interaction data, as well as tagging and notes to manage investor interactions and follow-ups. DealMaker also offers full payment reconciliation to ensure all books and records are accurate and companies using its technology can close quickly. Companies using DealMaker are able to maximize conversion on their deals and close their raises up to 75% faster.

Additional Benefits of DealMaker

  • Analytics – DealMaker has the most powerful analytical suite on the market. Real-time data provides information at a glance on the performance of the raise, including funnel analytics, conversion, investor progress and payments. DealMaker provides customers with the data they need to ensure their raise is progressing well. For marketed raises, including Regulation A+, Crowdfunding, 506c and Offering Memorandums, DealMaker has a full suite of marketing attribution tools to track the success of the marketing spend.
  • Shareholder Engagement and Management – The DMEngage shareholder management and engagement tool allows companies to share information, news releases and documents with current and potential investors and stakeholders before, during and after the raise. Investors and stakeholders also have access to all their information and documents in a branded portal. Whether it is a testing the waters campaign, uploading a DRS statement or sharing the companies’ latest quarterly results, DMEngage allows companies to manage all non-raise communication and engagement. DealMaker’s extensive research has shown that companies that engage their shareholders and stakeholders regularly raise more and faster and have more successful subsequent rounds.
  • Partners and Expertise – Having completed nearly 1,000 raises, DealMaker has unparalleled experience in capital raising. DealMaker’s customer success team prepares a detailed plan for each raise to ensure no detail is missed and customers are set up for success. DealMaker has also established the largest network of partners in the space. Whether customers need a marketing partner, a financial publisher, a broker dealer, a law firm, an auditor or investor relations, DealMaker can make referrals and ensure they have the right team in place for a successful raise.

Types of Raises

  • Regulation A+, 506c and Crowdfunding – Companies completing marketed raises on DealMaker own their brands and drive investors through a landing page that lives on the companies’ own website. Reg A+, 506c and Crowdfunding are the ultimate marketing tools, allowing companies to engage and grow their customer bases while raising capital. Marketed raises also have access to DealMaker’s best-in-class solutions, including digital payment tools, automated AML checks and Accredited Investor Verification services. As a result, companies raising via Reg A+, Reg CF and 506c on DealMaker have higher average investment amounts and conversion.
  • Seed Rounds, 506b, Accredited Investors and Funds – DealMaker’s solutions for traditional capital raises and funds start with a digitized subscription agreement and proprietary question flow. No matter how complex the raise, DealMaker’s question flow ensures subscription agreements are completed in minutes, with no deficiencies.

Executive Team

DealMaker Co-Founder and CEO Rebecca Kacaba has been honored as one of Lexpert’s ‘Top 40 Under 40’ in the legal field and was recognized as one of North America’s most innovative lawyers by the Financial Times. She practiced law on Bay Street for over 10 years and was co-chair of the Toronto Venture Technology and Emerging Growth Companies Group at a law firm while she worked as an M&A attorney in Canada’s financial district.

The company’s Co-Founder and Chief Strategy Officer, Mat Goldstein has practiced law on Wall Street and Bay Street, also gaining recognition from Financial Times as one of North America’s most innovative lawyers. Prior to launching DealMaker, he built and advised several startup enterprises.

DealMaker’s Chief Technology Officer is Geronimo de Abreu. With experience running his own development firm and scaling numerous companies through startup and growth, Mr. de Abreu has a diverse background in computer engineering, entrepreneurship and business strategy (MBA) to take DealMaker to the next level.

DealMaker’s VP of Sales and Marketing, Michael Werry has over a decade of experience successfully building and leading sales organizations in both the SaaS and financial services industries, ranging from startups to SME’s with over $750 million in annual revenue. He brings a wealth of experience in scaling organizations through periods of exponential growth.

The company’s VP Finance, Frank Jessop is a CFA, CPA, CA with a BMath in Stats from Waterloo. He provided leadership to the PwC emerging growth companies group before leading Sensibill through its Series B over the course of the last five years.

The company is also supported by advisers with decades of experience in the capital markets and their foundational technologies.


Recent News

chart

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, announced that it has received its first commercial sale of its PeroSTAR(TM) product. Two Israel-based, bell-pepper packing houses have ordered the product, which is formulated to ensure the safety and maximum shelf life of produce before it is exported. The packing houses tried the PeroSTAR treatment initially and, following positive results, decided to fully integrate the product into their treatment process. The packing houses are located in the Arava region, which produces approximately 60% of the fresh vegetables exported by Israel. Bell pepper, which are sold primarily to Russia, North America and the United Kingdom, are the leading export. This first commercial sale comes as the company also received regulatory approval of its product from the California Department of Pesticide Regulation (“CDPR”). “We are excited to see the first large-scale commercial implementation of our product for the bell pepper market, especially here in the heart of Israel’s thriving agriculture industry,” said Save Foods CEO Dan Sztybel in the press release. “We believe that the use of Save Foods’ treatment will help the Arava packing houses export produce of the highest quality without fungicides or a trace of hazardous residue.” To view the full press release, visit https://ibn.fm/IWdZY

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

  • SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
  • SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
  • SpuDefender, for controlling post-harvest potato sprouts; and
  • FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.

Applications

The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Monday’s trading session at $6, off by 1.6393%, on 17,283 volume with 133 trades. The average volume for the last 3 months is 17,283 and the stock's 52-week low/high is $4.20/$30.10.

Recent News

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC)

The QualityStocks Daily Newsletter would like to spotlight AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC).

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over the same period in 2020, and gross profit margin totaling 59.3%, representing an 8.8% increase from the year before. In addition, the average selling price of ANPC’s CDA-based tests was $71.6,  an increase of 72.3% from 2020. In addition, the company reported cash and cash equivalents of approximately $0.8 million for the nine-month period. Business highlights included AnPac’s acquisition of 60% equity interest in Anpai (Shanghai) Health Management Consulting Co. Ltd. as well as continued validation regarding the efficacy of its CDA testing obtained through clinical study follow-ups. To view the full press release, visit https://ibn.fm/RHRvT

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (CDA)

Cancer Differentiation Analysis (CDA) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

  • Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
  • Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
  • Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
  • Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
  • Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
  • Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://nnw.fm/L7css). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

AnPac Bio-Medical Science Co. Ltd. (ANPC), closed Monday’s trading session at $1.68, off by 1.1765%, on 287,416 volume with 927 trades. The average volume for the last 3 months is 287,291 and the stock's 52-week low/high is $1.36/$12.09.

Recent News

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF)

The QualityStocks Daily Newsletter would like to spotlight DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF).

DigiMax Global (CSE: DIGI) (OTC: DBKSF), a company that provides artificial intelligence (“AI”) and cryptocurrency technology solutions, today announced that it is adding ALTCOIN RADAR to its CryptoHawk trading tools. According to the update, the move represents the third feature expansion for CryptoHawk in addition to LONG-SHORT INDICATORS for bitcoin and ethereum, and TREND WATCH for select high-value market cap coins. The AI-driven ALTCOIN RADAR lists the top 100 Altcoins that meet two essential criteria including availability on a credible cryptocurrency trading platform and attributes that give it some likelihood of a near-term significant price increase. ALTCOIN RADAR offers a radical departure from predictive AI models that require historical financial and seasonal big data. Through combining all three predictive tools, CryptoHawk serves as a comprehensive, complete and powerful AI system compared to any similar offerings available in the market today. It also enables traders to move through three different trading styles depending on their appetite, including LONG-SHORT INDICATORS - day trading, TREND WATCH - swing trading and ALTCOIN RADAR - spot trading. To view the full press release, visit https://ibn.fm/3Yox1

DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals.

The company offers financial, business, and human capital AI predictive solutions to businesses, institutions, and consumers to improve decision-making.

The DigiMax core solutions are:

  1. CryptoHawk AI – CryptoHawk is a deep learning AI solution (SaaS) that monitors and analyzes live select cryptocurrencies and financial markets. The CryptoHawk AI solution is offered to retail clients as a monthly subscription. Generated data provides subscribers with price trend predictions for better investment strategies.
  2. Cryptocurrency Hedge Fund – A long/short cryptocurrency hedge fund for high net worth, institutional, and family office clients was launched on September 1, 2021. The company’s crypto hedge fund earns clients’ management and overall performance fees.
  3. Projected Personality Interpreter (PPI) – DigiMax solutions utilize AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services by measuring and correlating personal attributes.
  4. Navee Predict – DigiMax data scientists provide companies with the unprecedented power of enhancing decision-making by analyzing, detecting changes and forecasting patterns.

The company’s team has extensive experience in finance, trading, machine learning (ML), neural language processing, AI, big data, and cryptocurrency technology. DigiMax leverages AI and its expert team to translate data into actionable predictive insights across the financial, business, and human dimensions, enhancing the decision-making capacity of organizations. DigiMax is an official IBM Watson partner with more than 30 years in data science and artificial intelligence.

Solutions

Business and Financial Capital Solutions

CryptoHawk AI

CryptoHawk.ai is a cryptocurrency price and trend prediction solution offered as a web application (https://cryptohawk.ai) and a mobile application by the end of 2021. The value for the user is to capture gains and take advantage of volatility while reducing risk and engaging in smarter and simpler trading.

The key features:

  • Trend Prediction Indicator (“TPI”)
    The TPI is a superior model that leverages the cryptocurrencies analyzed by the AI and other market-driven data and policies to produce actionable predictions in the form of:
    • Prediction cards
    • Cryptocurrency graphs with optional market indicators
    • Email/SMS alerts
  • Trend Watch
    Trend Watch is a one-week look ahead machine learning prediction for a select portfolio of mature cryptocurrencies. Trend Watch predicts a trend being UP or DOWN and provides a price target. Users have access to:
    • A list of select cryptocurrencies with predictive graphs

The system alerts investors through email and text messages when a price trend changes, allowing users to act confidently.

Cryptocurrency Hedge Fund

On September 1, 2021, DigiMax launched its Cryptocurrency Hedge Fund to offer high net worth, institutional, and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms. The official launch is expected in the coming months.

The fund is led by 40-year hedge fund veteran Ian Hamilton and has an experienced investment and fund management team. This actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies.

AI Business Prediction as a Service

The company offers predictive insights to businesses through automation and its innovative and proprietary AI and ML technology. Traditional models are expensive, because they are created and developed by data scientists dedicated to solving specific business questions that require costly customization and weeks, if not months, of development. With DigiMax, companies have access to solutions and services at a fraction of the price of traditional and experimental approaches. By combining AI with ML prediction technology, the company delivers insights on:

  • Sales forecasts
  • Optimal inventory levels
  • Supply chain management
  • Invoice payment projections
  • Targeted segmentation for marketing campaigns

Human Capital Solutions

AI-Powered Projected Personality Interpreter

The Projected Personality Interpreter (“PPI”) evaluates and improves customers’ workforce, brand and culture by revealing the personality traits and sentiment buried in human expression. The PPI empowers organizations with comparative insight for better hiring decisions, reducing employment attrition and improving workplace culture.

PPI provides a comprehensive and complete solution, offering:

  • Recruitment campaign management
  • Custom questionnaires, desirable traits recipes, and group likenesses
  • Detailed personality reports to compare and contrast peers
  • API for advanced integration with alternative systems of record

DigiMax leverages IBM Watson and a custom algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, providing hiring managers with a comprehensive report that improves decision making and takes the bias out of the process. The company’s solution is currently in use by 17 law enforcement agencies in North America and is used across the 10 global recruitment brands of Shepherd Search Group.

Market Overview

The AI industry has a five-year CAGR of 18.4%, with revenues projected to reach $37.9 billion by 2024. Some more optimistic forecasts have the market worth as much as $15 trillion by 2030. It’s estimated that 80% of all emerging technologies in 2021 have AI foundations. About 40% of all businesses use AI in their operations. According to Industry Ark, artificial intelligence use in the recruitment market was valued at $580 million in 2019.

Management Team

Chris Carl, CEO

Chris Carl has over 20 years of experience as a public-company CEO and has built several successful businesses across multiple categories. He has a proven ability to lead and has a track record of execution, revenue growth, and value creation.

Thierry Hubert, CTO

Thierry Hubert has 30 years of technology experience with Fortune 100 companies worldwide and is an early pioneer in applying artificial intelligence to solve big data and unstructured information challenges with IBM as a Director of R&D in emerging technology, knowledge management, and process innovation. He has received awards, recognitions, and grants that contributed to his ongoing collaboration with industry leaders.

David Bhumgara, CFO

David Bhumgara is a senior finance executive with over 25 years of leadership experience and proven expertise in finance, financial reporting, accounting, corporate finance, budgeting, financial modeling, and mergers & acquisitions.

Damon Stone, Trading Strategy Advisor

Damon Stone is an experienced stock and crypto trader who works very closely with the Cryptodivine.ai data science team as a subject matter expert. During 15 years at Merrill Lynch as a market maker and proprietary trader, he traded many different sectors, culminating in heading up a $250 million trading desk.

Ross Power, Senior Innovation Engineer
Ross Power is an experienced technical system architect with a demonstrated history of working on advanced technologies, including AI algorithms, IoT solutions, 3D printing, Innovation in BCI (Brain-Computer Interfacing), and RC flight and navigation systems.

DigiMax Global Inc. (DBKSF), closed Monday’s trading session at $0.0619, off by 5.0613%, on 323,162 volume with 21 trades. The average volume for the last 3 months is 323,162 and the stock's 52-week low/high is $0.05/$0.70.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

America’s state-legal cannabis industry has been on a roll for the past few years. Cannabis companies have sold billions of dollars’ worth of products, created hundreds of thousands of new jobs and provided state coffers with millions of dollars in revenue. However, marijuana’s classification as a federally controlled substance has held the nascent but lucrative industry back, preventing cannabis companies from accessing crucial financial services, placing strict restrictions on marketing and advertising, and making interstate commerce nearly impossible. A group of cannabis activists is now urging businesses in the cannabis space to help them ask governors from key marijuana states to seek guidance from the federal government on what interstate cannabis trade between states with legal markets would look like. While this guidance would undoubtedly be provided by a federal cannabis reform bill, such legislation is likely years away, and the activists say guidance from the Justice Department would help regulate interstate cannabis trade in the interim. A sign-on letter by the Alliance for Sensible Markets campaign, a nonprofit coalition of business and advocacy leaders interested in building a sustainable legal cannabis industry, is currently circulating to drum up support for the cause. It would be interesting to see how the operations of established cannabis companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) would evolve once cannabis interstate commerce is no longer prohibited.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Monday’s trading session at $0.02955, off by 5.8917%, on 704,534 volume with 55 trades. The average volume for the last 3 months is 704,534 and the stock's 52-week low/high is $0.0261/$0.62.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading